| Issue Date | Title | Author(s) |
| 2023-11 | An analysis of the resource use and costs of febrile neutropenia events in pediatric cancer patients in Australia. | Vargas, C; Haeusler, GM; Slavin, MA; Babl, FE; Mechinaud, F; Phillips, R; Thursky, K; Lourenco, RDA; Australian PICNICC Study Group, |
| 2017-09-01 | Assessment of mental competency of patients, before surgery | Rolle, A; Vargas, C; Paredes, S; López, R |
| 2024-06-24 | Challenges for gene therapy in the financial sustainability of health systems: a scoping review. | Ossandon, H; Armijo, N; Vargas, C; Repetto, GM; Espinoza, MA |
| 2020-07-28 | Cost utility of a pharmacist-led minor ailment service compared with usual pharmacist care. | Dineen-Griffin, S; Vargas, C; Williams, KA; Benrimoj, SI; Garcia-Cardenas, V |
| 2024-10 | Cost-Effectiveness of Stereotactic Body Radiotherapy vs. Thermal Ablation for Primary Renal Cell Carcinoma: Analysis of the FASTRACK II Trial | Vargas, C; Carrello, J; Siva, S; Davey, R; Bressel, M; Pryor, DI; De Abreu Lourenco, R |
| 2021-09-16 | Cost-utility analysis of medication review with follow-up for cardiovascular outcomes: A microsimulation model. | Ahumada-Canale, A; Vargas, C; Martinez-Mardones, F; Plaza-Plaza, JC; Benrimoj, S; Garcia-Cardenas, V |
| 2018-09-01 | Costs and consequences of chronic pain due to musculoskeletal disorders from a health system perspective in Chile | Vargas, C; Bilbeny, N; Balmaceda, C; Rodríguez, MF; Zitko, P; Rojas, R; Eberhard, ME; Ahumada, M; Espinoza, MA |
| 2021-12 | Different Alternatives to Assess the Burden of Disease Using Attributable Fraction on a Disability Variable: The Case of Pain and Chronic Musculoskeletal Disorders in Chile. | Zitko, P; Bilbeny, N; Vargas, C; Balmaceda, C; Eberhard, ME; Ahumada, M; Rodríguez, MF; Flores, J; Markkula, N; Espinoza, MA |
| 2019-09-03 | Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison | Vargas, C; Balmaceda, C; Rodríguez, F; Rojas, R; Giglio, A; Espinoza, MA |
| 2015-11 | Estudio De Impacto Presupuestal De Daclatasvir Asociado A Asunaprevir Desde La Perspectiva Del Sistema De Salud Publico Chileno. | Vargas, C; Giglio, A; Soza, A; Espinoza, MA |
| 2017-12-01 | Estudio de impacto presupuestal de Daclatasvir asociado a Asunaprevir desde la perspectiva del sistema de salud público chileno | Vargas, C; Espinoza, MA; Giglio, A; Soza, A |
| 2021-02-05 | Medication review with follow-up for cardiovascular outcomes: a trial based cost-utility analysis. | Ahumada-Canale, A; Vargas, C; Balmaceda, C; Martinez-Mardones, F; Plaza-Plaza, JC; Benrimoj, S; Garcia-Cardenas, V |
| 2017-10 | PSY29 Estudio De Costo Efectividad Del Factor De Coagulación Recombinante VIII Unido A Proteina Fc Para El Tratamiento De La Hemofilia A En Chile | Vargas, C; Balmaceda, C; Rodriguez, F; Rojas, R; Espinoza, M |
| 2017-10 | PSY31 Estudio De Costo Efectividad Del Factor De Coagulación Recombinante IX Unido A Proteina Fc Para El Tratamiento De La Hemofilia B En Chile | Balmaceda, C; Vargas, C; Rodriguez, F; Rojas, R; Espinoza, M |
| 2016-11 | PSY89 Cost Effectiveness of Ruxolitinib Versus Best Available Therapy For The Treatment of Myelofibrosis From Public Health Perspective In Chile | Rojas, R; Balmaceda, C; Vargas, C; Espinoza, M |
| 2017-10 | PUK5 Cost Effectiveness of Peritoneal Dialysis Provision for the Treatment of Chronic Kidney Disease from Public Health Perspective in Chile | Rojas, R; Vargas, C; Balmaceda, C; Espinoza, M |
| 2024-12-28 | Systematic Literature Review of Access Pathways to Drugs for Patients with Rare Diseases. | Vargas, C; De Abreu Lourenco, R; Espinoza, M; Goodall, S |
| 2024-01 | Use of Health Technology Assessment for the Continued Funding of Health Technologies: The Case of Immunoglobulins for the Management of Multifocal Motor Neuropathy. | Vargas, C; Addo, R; Lewandowska, M; Haywood, P; De Abreu Lourenco, R; Goodall, S |
